Trivalent Salmonella Conjugate Vaccine (TSCV) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Trivalent Salmonella Conjugate Vaccine (TSCV) — Stella

Home/Trivalent Salmonella Conjugate Vaccine (TSCV)/

View on ClinicalTrials.gov

Recruiting

Back to Trivalent Salmonella Conjugate Vaccine (TSCV) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Mali

Centre for Vaccine Development (CVD-Mali), Bamako

Key details

Phase

Safety & dosing

Sponsor

University of Maryland, Baltimore

Collaborators

Bharat Biotech International, Wellcome Trust

Enrollment target

~800 participants

Started

April 2023

Primary completion

January 2027

Age range

12 Weeks – 35 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.